Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study.
Hiroshi InoueMichiaki UmeyamaTakako YamadaHiroyuki HashimotoAkira KomotoMasahiro YasakaPublished in: Journal of arrhythmia (2019)
No new safety signals of apixaban were identified in Japanese NVAF patients. Safety and effectiveness of apixaban were consistent with those in the ARISTOTLE study.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- randomized controlled trial
- end stage renal disease
- oral anticoagulants
- clinical practice
- systematic review
- direct oral anticoagulants
- left atrial
- public health
- left atrial appendage
- chronic kidney disease
- newly diagnosed
- heart failure
- ejection fraction
- peritoneal dialysis
- left ventricular
- percutaneous coronary intervention